Breaking News Instant updates and real-time market news.

JNJ

Johnson & Johnson

$131.82

0.29 (0.22%)

, BAYRY

Bayer

$133.06

0.01 (0.01%)

06:04
06/13/17
06/13
06:04
06/13/17
06:04

Bayer, J&J cleared of liability in second Xarelto trial, Reuters reports

Bayer (BAYRY) and Johnson & Johnson (JNJ) have been cleared of liability by a federal jury in the second trial stemming from thousands of lawsuits blaming injuries on Xarelto, a blood thinning drug, Reuters reports. Reference Link

JNJ

Johnson & Johnson

$131.82

0.29 (0.22%)

BAYRY

Bayer

$133.06

0.01 (0.01%)

  • 13

    Jun

  • 15

    Jun

  • 26

    Jun

JNJ Johnson & Johnson
$131.82

0.29 (0.22%)

06/06/17
WELS
06/06/17
NO CHANGE
WELS
Amazon may be the next threat to drug pricing, says Wells Fargo
After CNBC recently reported that Amazon (AMZN) is considering going into the prescription pharmacy business in the U.S., Wells Fargo surveyed nearly 2,900 U.S. adults and found that 54% of those polled said they would use or would probably use "Amazon Pharmacy." While the e-commerce giant has not confirmed its U.S. pharmacy interest, if it did enter the market analyst David Maris believes it could see fast adoption and "usher in a new age of price transparency." Maris also wonders if pharmacy "may be just the beginning" and if Amazon eyes the "even larger prize" of fully integrated digital healthcare. Publicly traded large-cap pharmaceuticals companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded retail pharmacy operators include CVS Health (CVS), Walgreens (WBA), Fred's (FRED) and Rite Aid (RAD).
06/07/17
FBCO
06/07/17
NO CHANGE
Target $38
FBCO
Outperform
ASCO meeting highlights pressure on Pfizer cancer assets, says Credit Suisse
Credit Suisse analyst Vamil Divan said he came away from the ASCO meeting feeling like positive progress by competitors is increasing the pressure on Pfizer's (PFE) cancer assets, specifically pointing to positive data for Roche's (RHHBY) Alecensa, Johnson & Johnson's (JNJ) Zytiga and Eli Lilly's (LLY) abemaciclib. Additionally, competition in the immune-oncology and PARP spaces will make it more challenging for Pfizer to gain traction, added Divan. He keeps an Outperform rating on Pfizer, citing valuation and its dividend yield, but he has concerns about its upcoming patent expirations and growth products.
06/09/17
FBCO
06/09/17
NO CHANGE
FBCO
Outperform
Tesaro prostate study suspension due to fast enrollment, says Credit Suisse
After speaking to Tesaro (TSRO), after they spoke to their partner Johnson & Johnson (JNJ), Credit Suisse analyst Alethia Young said the news of the companies' suspension of participant recruitment in the study of niraparib in prostate cancer is actually positive, since it is due to the trial enrolling faster than expected. The suspension has nothing to do with safety or efficacy and is not a clinical hold, but is due to having too many patients in the first part of trial, Young was told. She maintains an Outperform rating on Tesaro shares.
06/12/17
RHCO
06/12/17
NO CHANGE
RHCO
Misunderstanding creates buying opportunity in Tesaro stock, says SunTrust
SunTrust analyst Peter Lawson says that the suspension of participant recruitment by Johnson & Johnson (JNJ) for a study of Tesaro's (TSRO) PARP inhibitor Zejula in prostate cancer "is being incorrectly viewed as a clinical hold." After speaking with J&J, Lawson says that the suspension was not due to clinical or safety issues, but to overly fast enrollment. The analyst says that the early data on PARP inhibitors in prostate cancer has been "encouraging." He believes that the misunderstanding has created a buying opportunity in Tesaro stock. .
BAYRY Bayer
$133.06

0.01 (0.01%)

01/06/17
JPMS
01/06/17
NO CHANGE
Target $128
JPMS
Overweight
Monsanto shares are mispriced, says JPMorgan
JPMorgan analyst Jeffrey Zekauskas says Monsanto (MON) shares are mispriced and offer an attractive risk/reward proposition. A first catalyst for the shares would be regulatory agreement in the Dow Chemical (DOW)/DuPont (DD) transaction, Zekauskas tells investors in a research note. The analyst thinks a favorable resolution to the Dow/DuPont merger would be seen as improving the probability of the success of the Bayer/Monsanto transaction. He notes that Bayer has agreed to purchase Monsanto for $128 per share in cash, which represents 21% appreciation potential should the deal close by year-end. Zekauskas thinks a "reasonable floor" price for Monsanto shares, should the deal fail, is $102. He keeps an Overweight rating on the name with a $128 price target.
03/03/17
JPMS
03/03/17
NO CHANGE
Target $128
JPMS
Overweight
EU approvals of other ag deals may narrow Monsanto deal spread, says JPMorgan
JPMorgan analyst Jeffrey Zekauskas said commentary from the CEOs of DuPont (DD) and Syngenta (SYT) and press reports from Europe suggest that their deals with Dow Chemical (DOW) and ChemChina, respectively, are likely to be approved. Approvals from Europe for those deals may "trigger a meaningful closing of the arbitrage spread" in Monsanto (MON) shares versus Bayer's (BAYRY) offer price, Zekauskas tells investors. He recommends buying Monsanto shares at current levels for this reason, adding that he believes the shares would only fall about 2.5%, or down to $112, in the event of the Bayer deal falling through. Zekauskas keeps an Overweight rating and $128 price target on Monsanto shares, which closed yesterday at just below $115 per share.
04/06/17
JPMS
04/06/17
NO CHANGE
Target $128
JPMS
Overweight
Monsanto shares offer 'excellent' risk/reward proposition, says JPMorgan
JPMorgan analyst Jeffrey Zekauskas says shares of Monsanto (MON) at current levels offer an "excellent" risk/reward proposition. The analyst views capital appreciation potential to the end of 2017 as 11% or a 15% annual return. He sees downside risk of only 3%, to $112 per share, in the event that Bayer (BAYRY) is not able to consummate the acquisition. Zekauskas has increased confidence in the deal closing following recent regulatory rulings and keeps an Overweight rating on the name with a $128 price target.
04/10/17
PIPR
04/10/17
NO CHANGE
Target $17
PIPR
Overweight
OncoMed price target lowered to $17 from $26 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff lowered his price target for OncoMed (OMED) to $17 from $26 following two negative announcements, namely that the Phase II YOSEMITE study of demcizumab in first line pancreatic cancer failed and Bayer (BAYRY) returned rights for ipafricept and vantictumab. The analyst also notes that now partner Celgene (CELG) will review all data on demcizumab including Phase II DENALI non-small cell lung cancer data and Phase Ib combo data with KEYTRUDA, although he does not expect Celgene to exercise its option. Tenthoff reiterates an Overweight rating on OncoMed's shares.

TODAY'S FREE FLY STORIES

ISRG

Intuitive Surgical

$355.00

1.45 (0.41%)

, TRXC

TransEnterix

$3.66

-0.34 (-8.50%)

14:30
10/18/17
10/18
14:30
10/18/17
14:30
Earnings
On The Fly: What to watch in Intuitive Surgical earnings report »

Intuitive Surgical (ISRG)…

ISRG

Intuitive Surgical

$355.00

1.45 (0.41%)

TRXC

TransEnterix

$3.66

-0.34 (-8.50%)

MDT

Medtronic

$78.81

0.81 (1.04%)

JNJ

Johnson & Johnson

$140.38

-0.41 (-0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 20

    Oct

  • 23

    Oct

  • 25

    Oct

  • 27

    Oct

  • 06

    Nov

XLU

Utilities SPDR

$54.20

-0.15 (-0.28%)

14:30
10/18/17
10/18
14:30
10/18/17
14:30
Options
Defensive option play opened in SPDR Utility ETF »

Defensive option play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:25
10/18/17
10/18
14:25
10/18/17
14:25
General news
Treasury Action: yields remained steady below highs »

Treasury Action: yields…

CPK

Chesapeake Utilities

$81.80

0.75 (0.93%)

14:24
10/18/17
10/18
14:24
10/18/17
14:24
Initiation
Chesapeake Utilities initiated  »

Chesapeake Utilities…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

TGTX

TG Therapeutics

$8.43

-0.85 (-9.16%)

14:22
10/18/17
10/18
14:22
10/18/17
14:22
Recommendations
TG Therapeutics analyst commentary  »

TG Therapeutics selloff…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXT

Textron

$53.45

0.38 (0.72%)

14:20
10/18/17
10/18
14:20
10/18/17
14:20
Options
Call buyers in Textron Wednesday ahead of earnings Thursday morning »

Call buyers in Textron…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCA

HCA Healthcare

$77.57

0.75 (0.98%)

14:17
10/18/17
10/18
14:17
10/18/17
14:17
Downgrade
HCA Healthcare rating change  »

HCA Healthcare downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

$NSD

NASDAQ Market Internals

14:17
10/18/17
10/18
14:17
10/18/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
10/18/17
10/18
14:16
10/18/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$48.19

-0.21 (-0.43%)

, PM

Philip Morris

$112.63

-0.0199 (-0.02%)

14:15
10/18/17
10/18
14:15
10/18/17
14:15
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

VZ

Verizon

$48.19

-0.21 (-0.43%)

PM

Philip Morris

$112.63

-0.0199 (-0.02%)

DHR

Danaher

$85.92

0.66 (0.77%)

BK

BNY Mellon

$54.32

0.355 (0.66%)

BX

Blackstone

$33.59

0.365 (1.10%)

BBT

BB&T

$46.72

0.195 (0.42%)

TRV

Travelers

$129.36

0.71 (0.55%)

PPG

PPG

$112.93

-0.03 (-0.03%)

RCI

Rogers Communications

$53.46

-0.52 (-0.96%)

NUE

Nucor

$57.22

0.11 (0.19%)

DOV

Dover

$93.73

-0.32 (-0.34%)

GPC

Genuine Parts

$98.16

1.3 (1.34%)

TXT

Textron

$53.41

0.34 (0.64%)

DGX

Quest Diagnostics

$92.99

0.81 (0.88%)

ADS

Alliance Data

$229.96

3.015 (1.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 22

    Oct

  • 30

    Oct

  • 01

    Nov

  • 06

    Nov

  • 07

    Nov

  • 13

    Nov

  • 16

    Nov

  • 29

    Nov

  • 30

    Nov

  • 14

    Dec

AXP

American Express

$91.90

0.205 (0.22%)

, KMI

Kinder Morgan

$18.64

-0.04 (-0.21%)

14:15
10/18/17
10/18
14:15
10/18/17
14:15
Earnings
Notable companies reporting after market close »

Notable companies…

AXP

American Express

$91.90

0.205 (0.22%)

KMI

Kinder Morgan

$18.64

-0.04 (-0.21%)

CCI

Crown Castle

$101.10

-0.28 (-0.28%)

EBAY

eBay

$37.49

-0.28 (-0.74%)

UAL

United Continental

$68.23

0.72 (1.07%)

URI

United Rentals

$143.63

0.29 (0.20%)

AA

Alcoa

$47.17

-0.6 (-1.26%)

STLD

Steel Dynamics

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 19

    Oct

  • 19

    Oct

  • 22

    Oct

  • 08

    Nov

14:15
10/18/17
10/18
14:15
10/18/17
14:15
General news
Fed's Beige Book said growth was moderate to modest in all 12 Districts »

Fed's Beige Book…

JD

JD.com

$39.59

-0.08 (-0.20%)

14:10
10/18/17
10/18
14:10
10/18/17
14:10
Options
JD with notable call activity as shares rally »

JD with notable call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DECK

Deckers Brands

$66.02

0.71 (1.09%)

14:09
10/18/17
10/18
14:09
10/18/17
14:09
Hot Stocks
Marcato Capital raises stake in Deckers Brands to 8.4% from 6.1% »

On October 16, Marcato…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

SSNLF

Samsung

14:08
10/18/17
10/18
14:08
10/18/17
14:08
Periodicals
Samsung announces Bixby 2.0, Axios reports »

Samsung has announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 30

    Oct

SPX

S&P 500

14:03
10/18/17
10/18
14:03
10/18/17
14:03
Hot Stocks
Fed says economic activity increased in September through October »

The Federal Reserve says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LYV

Live Nation

$42.77

1.355 (3.27%)

14:01
10/18/17
10/18
14:01
10/18/17
14:01
Recommendations
Live Nation analyst commentary  »

Live Nation deal with NFL…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPPI

Spectrum

$14.46

0.52 (3.73%)

14:00
10/18/17
10/18
14:00
10/18/17
14:00
Options
Bullish option flow in Spectrum Pharm as shares surge »

Bullish option flow in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

LYV

Live Nation

$42.75

1.34 (3.24%)

14:00
10/18/17
10/18
14:00
10/18/17
14:00
Periodicals
Ticketmaster, NFL extend ticketing relationship for five years, SBD says »

Live Nation's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEOS

Neos Therapeutics

$8.10

0.1 (1.25%)

13:52
10/18/17
10/18
13:52
10/18/17
13:52
Recommendations
Neos Therapeutics analyst commentary  »

Neos Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDX

FedEx

$222.28

2.18 (0.99%)

13:52
10/18/17
10/18
13:52
10/18/17
13:52
Hot Stocks
FedEx long-term goals include increasing EPS 10%-15% per year »

Long-term financial goals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 19

    Oct

  • 09

    Nov

CAH

Cardinal Health

$65.46

0.38 (0.58%)

13:48
10/18/17
10/18
13:48
10/18/17
13:48
Hot Stocks
Cardinal Health moved lower after STAT story on California license »

Shares of Cardinal Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

VIA

Viacom

$33.95

0.2 (0.59%)

, VIAB

Viacom

$26.57

0.31 (1.18%)

13:47
10/18/17
10/18
13:47
10/18/17
13:47
Periodicals
Viacom, Charter agree to network deal for basic package, Reuters reports »

Viacom (VIA, VIAB) and…

VIA

Viacom

$33.95

0.2 (0.59%)

VIAB

Viacom

$26.57

0.31 (1.18%)

CHTR

Charter

$357.84

-4.76 (-1.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 16

    Nov

13:45
10/18/17
10/18
13:45
10/18/17
13:45
General news
Breaking General news story  »

September Beige Book to…

CAH

Cardinal Health

$65.50

0.415 (0.64%)

13:44
10/18/17
10/18
13:44
10/18/17
13:44
Periodicals
California wants to revoke Cardinal facility's wholesale license, STAT reports »

California wants to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.